ABSTRACT
Aim Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose COVID-19 vaccines may offer increased immunogenicity.
Materials & methods A pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50 or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes were seroconversion, total and neutralizing antibody titers, and cellular immune responses.
Results mRNA-1273 was associated with a significantly higher seroconversion likelihood (relative risk, 1.11 [95% CI, 1.08, 1.14]; P<0.0001; I2=66.8%) and higher total antibody titers (relative increase, 50.45% [95% CI, 34.63%, 66.28%]; P<0.0001; I2=89.5%) versus BNT162b2. mRNA-1273 elicited higher but statistically nonsignificant relative increases in neutralizing antibody titers and cellular immune responses versus BNT162b2.
Conclusion Higher-dose mRNA-1273 had increased immunogenicity versus BNT162b2 in IC patients.
Competing Interest Statement
SK, KH, XW, PS, MA, AK, SV, MN, and NK are employees of ICON plc, a clinical research organization paid by Moderna, Inc., to conduct the study. AS is an independent epidemiology consultant/director of Data Health Ltd, which provides health data consultancy services, and was paid by Moderna, Inc., to conduct aspects of this study. MTB-J and NVdV are employees of Moderna, Inc., and hold stock/stock options in the company.
Funding Statement
This study was funded by Moderna, Inc. Authors employed by Moderna, Inc., were involved in the study design, analysis and interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
